| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Hesperetin 7-O-glucoside targets multiple pathways. It is a potent human HMG-CoA reductase inhibitor, which is the key enzyme in cholesterol biosynthesis. The compound effectively inhibits the growth of Helicobacter pylori. Its antioxidant effects involve scavenging free radicals, and its anti-inflammatory effects involve modulating inflammatory pathways.
|
|---|---|
| ln Vitro |
Hesperetin 7-O-glucoside demonstrates potent in vitro inhibition of human HMG-CoA reductase. It effectively inhibits the growth of Helicobacter pylori. The compound exhibits antioxidant activity by scavenging free radicals and anti-inflammatory activity by modulating inflammatory pathways. It also shows antihypertensive effects.
|
| ln Vivo |
Hesperetin 7-O-glucoside has demonstrated in vivo activity in human studies, where it can reduce blood pressure in healthy volunteers. Its antioxidant, anti-inflammatory, and cardiovascular benefits have been observed. Further in vivo studies are needed to fully characterize its therapeutic potential in various disease models.
|
| Enzyme Assay |
In vitro enzyme assays for hesperetin 7-O-glucoside involve measuring its inhibition of HMG-CoA reductase activity. The assay typically uses purified enzyme and measures the conversion of HMG-CoA to mevalonate in the presence of the compound. Antibacterial activity against H. pylori is assessed using standard microbial growth inhibition assays. Antioxidant activity is measured using DPPH or ABTS assays.
|
| Cell Assay |
In vitro cellular assays for hesperetin 7-O-glucoside involve treating cells with varying concentrations of the compound and measuring its effects on cholesterol synthesis, inflammatory markers, or oxidative stress. Antibacterial activity against H. pylori is assessed by culturing the bacteria in the presence of the compound and measuring growth inhibition.
|
| Animal Protocol |
In vivo animal experiments for hesperetin 7-O-glucoside are not extensively documented. If used in animal models, typical protocols would involve administering the compound to models of hyperlipidemia, hypertension, or H. pylori infection and evaluating efficacy by measuring lipid profiles, blood pressure, or bacterial load.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for hesperetin 7-O-glucoside indicate that it is a flavanone glycoside with enhanced hydrophilicity compared to aglycone forms. The compound has a molecular weight of 464.43 and a molecular formula of C22H24O11. Its absorption, distribution, metabolism, and excretion properties are characteristic of flavonoid glycosides.
|
| Toxicity/Toxicokinetics |
Hesperetin 7-O-glucoside has shown low toxicity in research studies. As a natural product-derived compound, it is generally considered safe at therapeutic doses. However, comprehensive toxicological studies have not been reported. The compound is intended for research use only. Standard laboratory safety precautions should be followed when handling this compound.
|
| References |
|
| Additional Infomation |
Hesperetin 7-O-β-D-glucoside is a flavanone 7-O-β-D-glucoside, its flavanone component being Hesperetin. It is a metabolite. It is a flavanone 7-O-β-D-glucoside, a monomethoxyflavanone, a 3'-hydroxyflavanone, a dihydroxyflavanone, a monosaccharide derivative, and a 4'-methoxyflavanone. Functionally, it is related to Hesperetin. Hesperetin 7-O-glucoside has been found in Cunila, and relevant data are available. See also: Hesperetin 7-glucoside (note moved to).
Hesperetin 7-O-glucoside (CAS#: 31712-49-9) has the molecular formula C22H24O11 and a molecular weight of 464.43. It is a flavanone glycoside derived from hesperetin, found in citrus fruits. The compound is a potent HMG-CoA reductase inhibitor and inhibits the growth of Helicobacter pylori. It has antioxidant, anti-inflammatory, and cardiovascular benefits. |
| Molecular Formula |
C22H24O11
|
|---|---|
| Molecular Weight |
464.42
|
| Exact Mass |
464.131
|
| CAS # |
31712-49-9
|
| PubChem CID |
147394
|
| Appearance |
White to off-white solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Boiling Point |
807.1±65.0 °C at 760 mmHg
|
| Flash Point |
282.0±27.8 °C
|
| Vapour Pressure |
0.0±3.0 mmHg at 25°C
|
| Index of Refraction |
1.672
|
| LogP |
0.52
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
33
|
| Complexity |
677
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
COC1=C(C=C(C=C1)[C@@H]2CC(=O)C3=C(C=C(C=C3O2)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)O
|
| InChi Key |
ADSYMQORONDIDD-ZJHVPRRPSA-N
|
| InChi Code |
InChI=1S/C22H24O11/c1-30-14-3-2-9(4-11(14)24)15-7-13(26)18-12(25)5-10(6-16(18)32-15)31-22-21(29)20(28)19(27)17(8-23)33-22/h2-6,15,17,19-25,27-29H,7-8H2,1H3/t15-,17+,19+,20-,21+,22+/m0/s1
|
| Chemical Name |
(2S)-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,3-dihydrochromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 25 mg/mL (53.83 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.48 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.48 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1532 mL | 10.7661 mL | 21.5322 mL | |
| 5 mM | 0.4306 mL | 2.1532 mL | 4.3064 mL | |
| 10 mM | 0.2153 mL | 1.0766 mL | 2.1532 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
